SCHEMBL20046530

SCHEMBL20046530

COC(=O)c1c(CBr)ccc(Br)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
TSHR P16473 2/20 0.37
MAPK1 P28482 1/20 0.37
CCR6 P51684 1/20 0.37
HKDC1 Q2TB90 1/20 0.37
MEP1B Q16820 2/20 0.36
NOTUM Q6P988 1/20 0.36
SOS1 Q07889 1/20 0.35
BDKRB1 P46663 7/20 0.35
MAPT P10636 1/20 0.34
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
GCGR P47871 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30571178 1.00 CA12 (0.38) CA12CA1CA2CA7CA9
SCHEMBL31284647 0.89 CA12 (0.39) CA12CA1CA2CA7CA9
SCHEMBL29570128 0.89 CA12 (0.39) CA12CA1CA2CA7CA9
SCHEMBL6119468 0.87 CA12 (0.38) CA12CA1CA2CA7CA9
SCHEMBL31246182 0.85 MEP1B (0.40) CA12CA1CA2CA7CA9
SCHEMBL30765131 0.84 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL20576640 0.84 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL23362809 0.84 MEP1B (0.43) CA12CA1CA2CA7CA9
SCHEMBL10200294 0.83 HPGDS (0.38) CA12CA1CA2CA7CA9
SCHEMBL1649000 0.82 CA12 (0.43) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 WO disclosed
US-20250084056-A1 SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-03-13 US disclosed
US-20230312564-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312564-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312564-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2023-10-05 US disclosed
CN-114075196-B Aromatic ring lactam compound, preparation method and application thereof 上海凌达生物医药有限公司 2023-09-15 CN disclosed
EP-4206199-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Ringene BioPharma Co., Ltd. (CN) 2023-07-05 EP disclosed
CN-114075196-A Aromatic ring-lactam compound, preparation method and application thereof 上海凌达生物医药有限公司 2022-02-22 CN disclosed
EP-3523289-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF Araxes Pharma LLC (US) 2019-08-14 EP disclosed
US-10377743-B2 Inhibitors of RAS and methods of use thereof ARAXES PHARMA LLC (US) 2019-08-13 US disclosed
US-20180127396-A1 INHIBITORS OF RAS AND METHODS OF USE THEREOF ARAXES PHARMA LLC 2018-05-10 US disclosed
WO-2018068017-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF ARAXES PHARMA LLC (US) 2018-04-12 WO disclosed
WO-2018068017-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF ARAXES PHARMA LLC (US) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312564-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, WEE2, WASF2 CA12 4696/4885CA1 4660/4885CA2 4651/4885
US-20250084056-A1 SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS CCNA1, CCNI, CCNE1 CA12 4637/4885CA1 3806/4885CA2 4085/4885
US-10377743-B2 Inhibitors of RAS and methods of use thereof KRAS, NRAS, HRAS CA12 3382/4885CA1 2064/4885CA2 1601/4885
US-20180127396-A1 INHIBITORS OF RAS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS CA12 3529/4885CA1 2486/4885CA2 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.